Enovis (NYSE:ENOV) Sets New 1-Year Low – Time to Sell?

10 Sep 2026, 15:41 by Michael Walen · The Markets Daily

Enovis Corporation (NYSE:ENOV – Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $18.50 and last traded at $18.70, with a volume of 127204 shares traded. The stock had previously closed at $19.03.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Canaccord Genuity Group decreased their price objective on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday, August 17th. Citizens Jmp dropped their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a report on Wednesday, September 2nd. UBS Group reissued a “buy” rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Wells Fargo & Company cut their target price on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 2nd. Finally, Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $40.38.

View Our Latest Stock Analysis on ENOV

Enovis Stock Down 1.4%

The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The stock has a market capitalization of $1.08 billion, a PE ratio of -0.97 and a beta of 1.31. The business has a 50 day moving average of $25.40 and a two-hundred day moving average of $24.16.

Enovis (NYSE:ENOV – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. The company had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts predict that Enovis Corporation will post 3.15 EPS for the current year.

Insider Buying and Selling

In other news, CEO Damien Mcdonald bought 13,035 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was bought at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the transaction, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Oliver Engert bought 5,140 shares of the stock in a transaction on Thursday, September 3rd. The stock was purchased at an average price of $19.46 per share, with a total value of $100,024.40. Following the completion of the purchase, the insider owned 61,238 shares of the company’s stock, valued at $1,191,691.48. This represents a 9.16% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 24,293 shares of company stock worth $470,519. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

A number of large investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its holdings in shares of Enovis by 12.5% during the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after purchasing an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after buying an additional 73,116 shares during the last quarter. Empowered Funds LLC grew its stake in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares in the last quarter. Finally, Amundi increased its position in Enovis by 24,405.0% during the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after buying an additional 9,762 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

About Enovis

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.